Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glenzocimab in SARS-Cov-2-related ARDS
NCT04659109Phase 2Completed
- Sponsor
- Acticor Biotech
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of glenzocimab in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Acticor Biotech. Started Dec 2020; status: completed.
02
Drugs
glenzocimab
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04659109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659109.